Cargando…
The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran
INTRODUCTION: The decision to start insulin therapy is often difficult. Determining the barriers against insulin therapy initiation can facilitate care and treatment strategies. The aim of this study was to evaluate the barriers against initiating insulin therapy among patients with diabetes living...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689560/ https://www.ncbi.nlm.nih.gov/pubmed/31496772 http://dx.doi.org/10.2147/DMSO.S200867 |
_version_ | 1783443043624419328 |
---|---|
author | Shafie Pour, MR Sadeghiyeh, T Hadavi, M Besharati, M Bidaki, R |
author_facet | Shafie Pour, MR Sadeghiyeh, T Hadavi, M Besharati, M Bidaki, R |
author_sort | Shafie Pour, MR |
collection | PubMed |
description | INTRODUCTION: The decision to start insulin therapy is often difficult. Determining the barriers against insulin therapy initiation can facilitate care and treatment strategies. The aim of this study was to evaluate the barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran. METHODS: This descriptive study was conducted on 214 patients referred to the Diabetes Center of Yazd University of Medical Sciences in 2015. Participants were randomly selected, and then they completed the insulin noncompliance questionnaire (20 questions). The percentage of adherence and the factors contributing to nonadherence to insulin therapy were analyzed using descriptive statistics, the Kruskal–Wallis test, and the Mann–Whitney test. RESULTS: The most prevalent reason for insulin therapy refusal was expecting a new method of diabetes treatment (54.7%), followed by requiring someone else to administer the injection (19.2%), fear of needles, cost, traveling (18.7%), and stress/emotional problems (18.2%). Lack of trust in the physician was the least restrictive reason for nonadherence to insulin therapy. CONCLUSION: The most common reason given for insulin therapy refusal was the lack of adequate education. Therefore, specialized educational interventions can help minimize barriers and improve patients’ outcomes. |
format | Online Article Text |
id | pubmed-6689560 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-66895602019-09-06 The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran Shafie Pour, MR Sadeghiyeh, T Hadavi, M Besharati, M Bidaki, R Diabetes Metab Syndr Obes Original Research INTRODUCTION: The decision to start insulin therapy is often difficult. Determining the barriers against insulin therapy initiation can facilitate care and treatment strategies. The aim of this study was to evaluate the barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran. METHODS: This descriptive study was conducted on 214 patients referred to the Diabetes Center of Yazd University of Medical Sciences in 2015. Participants were randomly selected, and then they completed the insulin noncompliance questionnaire (20 questions). The percentage of adherence and the factors contributing to nonadherence to insulin therapy were analyzed using descriptive statistics, the Kruskal–Wallis test, and the Mann–Whitney test. RESULTS: The most prevalent reason for insulin therapy refusal was expecting a new method of diabetes treatment (54.7%), followed by requiring someone else to administer the injection (19.2%), fear of needles, cost, traveling (18.7%), and stress/emotional problems (18.2%). Lack of trust in the physician was the least restrictive reason for nonadherence to insulin therapy. CONCLUSION: The most common reason given for insulin therapy refusal was the lack of adequate education. Therefore, specialized educational interventions can help minimize barriers and improve patients’ outcomes. Dove 2019-08-07 /pmc/articles/PMC6689560/ /pubmed/31496772 http://dx.doi.org/10.2147/DMSO.S200867 Text en © 2019 Shafie Pour et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Shafie Pour, MR Sadeghiyeh, T Hadavi, M Besharati, M Bidaki, R The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran |
title | The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran |
title_full | The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran |
title_fullStr | The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran |
title_full_unstemmed | The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran |
title_short | The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran |
title_sort | barriers against initiating insulin therapy among patients with diabetes living in yazd, iran |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689560/ https://www.ncbi.nlm.nih.gov/pubmed/31496772 http://dx.doi.org/10.2147/DMSO.S200867 |
work_keys_str_mv | AT shafiepourmr thebarriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran AT sadeghiyeht thebarriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran AT hadavim thebarriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran AT besharatim thebarriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran AT bidakir thebarriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran AT shafiepourmr barriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran AT sadeghiyeht barriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran AT hadavim barriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran AT besharatim barriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran AT bidakir barriersagainstinitiatinginsulintherapyamongpatientswithdiabeteslivinginyazdiran |